Category Archives: Biotechnology

GlaxoSmithKline (GSK) - Get GlaxoSmithKline Plc Reportand its U.S. partnerVir Biotechnology (VIR) - Get Vir Biotechnology, Inc. Reportsaid Tuesday that theirCOVID antiviral is effective against all mutations of the Omicron variant, sending shares in theSan Francisco-based drugmaker sharply higher in pre-market trading.

The pair said their COVID treatment, known as 'sotrovimab' -- which was approved for use in the United Kingdom earlier this month -- was found to have worked against the 37 different mutations in the spike protein of the Omicron variant in data published from a recently-completed study.

GlaxoSmithKline and Vir Bio also noted thatsotrovimabretained its 'in vitro activity' against key individual mutations of the Omicron variant, based on what it calledinitial preclinical data generated through "pseudo-virus testing".

Sotrovimab is the first monoclonal antibody to report preclinical data demonstrating activity against all tested SARS-CoV-2 variants of concern and interest to date, including Omicron, as well as the still prevalent and highly contagious Delta variant," said CEO George Scangos.

"Given the less than three-fold neutralization shift demonstrated in the pre-clinical pseudo-virus assay, we are confident that sotrovimab will continue to provide significant benefit for the early treatment of patients hoping to avoid the most severe consequences of COVID-19.

Vir Bio shares were marked 9.75% higher in pre-market trading Tuesday to indicate an opening bell price of $42.. each. GlaxoSmithKline's U.S.-listed shares edged 0.8% higher to $42.10 each.

The World Health Organization said Tuesday that it has identified 432 cases of the Omicron variant, over its 21 member states, as of December 6, adding that there isn't enough data as yet to determine if the variant will be more or less transmissible -- or indeed severe -- than previous mutations.

Read this article:
GlaxoSmithKline, Vir Biotechnology Say COVID Therapy Effective Against Omicron Variant - TheStreet

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) increased by over 11% today. Investors are responding positively to GlaxoSmithKline and Vir Biotechnology today announcing an update to preclinical data on bioRxiv1, a preprint server, demonstrating that sotrovimab, an investigational monoclonal antibody, retains in vitro activity against the full known Omicron spike protein, the new SARS-CoV-2 variant (B.1.1.529).

This preclinical data was generated through pseudo-virus testing of the combined known mutations of the Omicron variant, which included the maximum number of changes (37 mutations) identified to date in the spike protein. And these findings build on the initial preclinical data generated through pseudo-virus testing, provided last week, showing sotrovimab retained in vitro activity against key individual mutations of the Omicron variant, including those found in the binding site of sotrovimab. This data adds to the growing body of preclinical evidence demonstrating that sotrovimab retains activity against all tested variants of concern.

KEY QUOTES:

Sotrovimab is the first monoclonal antibody to report preclinical data demonstrating activity against all tested SARS-CoV-2 variants of concern and interest to date, including Omicron, as well as the still prevalent and highly contagious Delta variant. Given the less than three-fold neutralization shift demonstrated in the pre-clinical pseudo-virus assay, we are confident that sotrovimab will continue to provide significant benefit for the early treatment of patients hoping to avoid the most severe consequences of COVID-19.

George Scangos, Ph.D., Chief Executive Officer of Vir

From the outset of our collaboration with Vir we hypothesized that sotrovimab would have a high barrier to resistance and thus could deliver best-in-class potential for the early treatment of patients with COVID-19. These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO, and we look forward to discussing these results with regulatory authorities around the world.

Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Go here to see the original:
Vir Biotechnology Stock (VIR): Why The Price Jumped Today - Pulse 2.0

BOSTON--(BUSINESS WIRE)-- GRO Biosciences Inc. (GRObio), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the appointment of Bruce Beutel, PhD to its Board of Directors and its upcoming participation and activity during J.P. Morgan Health Care Week in January 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005324/en/

GRObio appointed Bruce Beutel, PhD to its Board of Directors. (Photo: Business Wire)

GRObio appointed Bruce Beutel, PhD to its Board of Directors. Dr. Beutel is an expert in novel therapeutics and platform research, business development, and company creation. Over the course of his career, he has focused on strategy, vision, team building and value creation at the interface of science and business, particularly for emerging biotechnology companies. Dr. Beutel has held several C-level roles in multiple biotechnology companies including founding Chief Operating Officer and Chief Business and Strategy Officer at Dewpoint Therapeutics. He also has served in leadership roles at both Abbott and Merck. Dr. Beutel now serves as Venture Partner with Qiming Venture Partners USA. Dr. Beutel received his PhD in Molecular Biology from University of WisconsinMadison.

We are thrilled to have Bruce join our Board of Directors. His long-standing experience in building successful platform biotechnology companies will help ensure GRObios technology reaches its greatest potential, said Daniel J. Mandell, PhD, Co-Founder and Chief Executive Officer of GRO Biosciences. Bruces depth of experience from founding and leading biotechnology companies, to serving in business development, operations and strategy roles will be a great asset to GRObio as we continue to advance our platform, pipeline and partnerships.

GRObio at JPM

GRObio senior leadership will attend the J.P. Morgan Health Care Conference from January 10 14 and will participate in in-person meetings as well as virtual meetings via the Biotechnology Innovation Organization (BIO) Partnering platform.

To arrange a meeting with GRObio leadership, contact Tad Stewart, GRObios Chief Business Officer via email at tad.stewart@grobio.com.

About GRO Biosciences

GRO Biosciences (GRObio) is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The Company is transforming treatments for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries. The Companys NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system. GRObio, co-founded by Dr. George Church of Harvard Medical School in 2016, is headquartered in Cambridge, MA. Find GRObio on LinkedIn, Twitter, Instagram, Facebook and the web at grobio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005324/en/

See original here:
GRO Biosciences Announces Appointment of Bruce Beutel, PhD to Board of Directors and JP Morgan Health Care Conference Week Activities - BioSpace

Though we still hear some moaning and groaning about GMOs genetically modified organisms it primarily comes from a small and very vocal group. Most people simply arent concerned about GMOs as they focus on real and pressing issues, like the climate crisis and COVID-19 global pandemic. Even anti-GMO groups are turning their attention elsewhere as they redirect their conflict-driven business models to more lucrative topics, such as COVID conspiracy theories and peddling miracle cures. While the GMO debate has been percolating for nearly three decades, data indicate its now over. Here are five facts to support that conclusion.

Almost every scientific institution in the world recognizes the safety of genetically modified crops. Some 3,000 scientific studies have assessed the safety of these crops, in terms of human and environmental health, and 284 institutions globally recognize that GMO crops are safe. These include the Royal Society of Medicine, the American Medical Association, The World Academy of Sciences, the World Health Organization, the European Commission and the American Association for the Advancement of Science, among many others.

The most robust study was conducted by the National Academies of Science, which brought in experts from a wide range of food and agriculture disciplines to look at data compiled over the years. They all came to the same conclusion: No substantiated evidence of a difference in risks to human health between conventional and currently commercially available GM crops and no conclusive cause-and-effect evidence of environmental problems from GM crops.

As part of our work at the Alliance for Science, weve been using Cision media monitoring tools since 2018 to track the global conversation around GMOs. In 2020, we found that GMO visibility decreased by 26 percent from 2019 and the volume of social media posts on the topic decreased by 39 percent. Additionally, data show the average monthly favorability of the GMO conversation in both traditional and social media increased from 68 percent in 2019 to 78 percent in 2020. The shift was most pronounced in the free-for-all of social media, where favorability increased from just 60 percent in 2019 to 78 percent in 2020. Social media also saw a decrease in anti-GMO conspiratorial content in 2020, likely due to accounts that tend to promote such messages increasingly focusing on various COVID conspiracies. Meanwhile, top tier media like Reuters, CGTV, CNN and New Scientist replaced anti-GMO stalwarts, such as GM Watch and GMO-Free USA, as the top Twitter influencers on the topic in 2020. Journalists are increasingly reporting on GMOs in a positive or neutral tone that reflects the science and scientific consensus on safety.

Young people embrace technology in general as a tool for feeding the many while sparing the planet. Receptivity among this demographic is also improving as awareness grows about the role of GM crops in reducing agricultures environmental impact and greenhouse gas emissions associated with global warming. A recent unpublished survey by the Center for Food Integrity found that Gen Z and millennials tend to be more accepting of agricultural technology than their older counterparts and to see it as offering powerful solutions to humanitys problems.

Farmers around the world can see value in every harvest, as they achieve higher yields with less investment in fertilizers, pesticides and other inputs. This is true for both smallholder farmers and those with much larger operations. For example, smallholder farmers in Bangladesh cut their pesticide use by 62 percent and increased their profits six-fold by growing brinjal (eggplant) that has been genetically modified to resist the destructive fruit and shoot borer. Due to these benefits, biotechnology is the fastest-adopted crop technology in the world, increasing 112-fold from 1996 to 2019. Some 29 countries 56 percent of them developing nations grew 190.4 million hectares of GM crops in 2019.

Notably, GMO crop adoption is accelerating in South Asia and Africa. After years of debate, the Philippines this year approved the cultivation of Golden Rice and Bt eggplant is moving through the regulatory process. Nigeria, often called the Giant of Africa, has already approved insect-resistant GM cowpea and cotton. It is now moving to adopt drought-tolerant and insect-resistant maize (corn) and GM NEWEST rice that is water- and nitrogen-use efficient and tolerant of salty soils. Kenya, despite having a GMO moratorium in place, has adopted GM cotton and is expected to approve GM maize in 2022. This trend is likely to continue as African scientists are increasingly engaged in research that applies the tools of biotechnology to crops that are key to securing the livelihoods of smallholder farmers and supporting food security.

Brazil, whose agricultural sector is dominated by smallholder farmers, is emerging as another GM powerhouse. In addition to growing commodity crops like GM corn and soybean, Brazilian public sector researchers developed a GM pinto bean that resists a devasting plant disease. It is now being sold in the countrys grocery stores. Brazil this year also became the first country to approve the importation of flour made from GM wheat, giving a boost to a crop developed in neighboring Argentina, which has also embraced agricultural biotechnology. Its exciting to see government leaders put aside the politics and focus on what their nations and their farmers need.

Though consumers have been benefitting from GM crops without even realizing it, through higher yields that keep prices in check and reduced pesticide loads that make food healthier, nearly all the GM crops developed to date have catered to the needs of farmers. It is likely that consumers will similarly come to love GM crops as new products enter the market with traits that directly benefit them and/or reflect their values, such as enhanced nutrition, better taste and more sustainable approaches to agriculture.

Though Europeans are widely perceived as an anti-GMO stalwarts, concern about GMOs there dropped from 66 percent in 2010 to just 27 percent in 2019. That shift in sentiment is good news for countries that are influenced by European NGOs and policies that stand in the way of farmers accessing the benefits of GM crops.

The use of biotechnology to develop effective and safe COVID-19 vaccines has had a halo effect on GMO crops, improving public awareness about the technology and its benefits in both health and agricultural applications. Similarly, the advent of new tools like CRISPR and synthetic biology, which hold great promise for making agriculture more sustainable and producing food products with consumer benefits, are likely to reinforce the positive trends. Indeed, our media monitoring is already showing the conversation around gene editing is even more favorable than the one about GMOs, in both social and traditional media.

While its heartening to see the GMO debate dwindle, much time and momentum has been lost to addressing the opposition. Just 13 GM crops are currently on the market globally, most of them international commodity crops that support industry and livestock production. Only five cowpea, papaya, brinjal, pinto beans and Golden Rice are niche crops and food staples. This travesty is due primarily to misinformation (fear mongering) spread by GM opponents and the regulatory roadblocks they champion that make it difficult and expensive for public sector scientists and start-ups to develop crops with the traits that are useful to the people in their societies.

The GMO debate, driven largely by ill-informed or idle opposition from the well-fed West, is over. In a world wracked by a mutating virus and rising temperatures, action and answers matter more than opinions and rhetoric. The conversation we need to have now is about broadening access to the tools of biotechnology. Simply put, farmers need greater access to improved seeds and young scientists need more access to innovative tools.

It is estimated that agriculture will need to increase production by 70 percent to feed the worlds 9 billion citizens by 2050. And it needs to do this while greatly curbing its current impacts. Agriculture currently accounts for 50 percent of all global topsoil loss, 33 percent of the worlds GHG emissions, 75 percent of the nitrogen emissions and 80 percent of the deforestation worldwide. Biotechnology offers hope for shrinking agricultures footprint while producing more and better food. Lets stop the chatter and use todays tools to save the planet tomorrow.

Image: A smallholder farmer in Bangladesh shows off his harvest of GM brinjal. Photo: Alliance for Science

Follow this link:
5 reasons why the GMO debate is over - Alliance for Science

HOUSTON, Dec. 9, 2021 /PRNewswire/ --Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the initiation of a Phase 1 clinical trial to investigate tegavivint in a first-line combination study with osimertinib in previously untreated patients with metastatic epidermal growth factor receptor (EGFR)-positive Non-Small Cell Lung Cancer (NSCLC). Tegavivint is a potent and selective first-in-class small molecule inhibitor of Transducin beta-like Protein One (TBL1), a novel downstream target in the Wnt/beta-catenin signaling pathway. The trial (NCT04780568) is sponsored by The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), and led by Regan M. Memmott, M.D., Ph.D., an OSUCCC James oncologist.

An important clinical challenge with EGFR-TKIs (tyrosine kinase inhibitors), including osimertinib, is that while such drugs are recommended as first line therapy in metastatic EGFR-positive NSCLC, this class of drugs enriches for "drug-tolerant persister cells" (DPCs), resulting in the eventual development of resistance. Researchers at OSUCCC - James determined that enrichment of DPC's by osimertinib is driven by activation of beta-catenin, and further demonstrated that administration of tegavivint in combination with osimertinib prevented osimertinib-induced enrichment of DPCs. Use of this combination also showed deeper anti-tumor responses and prolonged overall survival in mouse models of EGFR-mutant NSCLC.1

"For the estimated 15-30% of patients in the U.S. who have EGFR-positive NSCLC, treatment with EGFR-TKIs, such as osimertinib, has been shown to be very effective, but unfortunately patients will relapse as a result of their tumors eventually developing resistance," said Dr. Memmott, principal investigator for the study. "Research conducted at OSUCCC James suggests that combining tegavivint with osimertinib could curtail the osimertinib-induced drug-tolerant persister cells from developing due to tegavivint's ability to act as a beta-catenin inhibitor via TBL1 inhibition. This new Phase 1 clinical trial evaluates osimertinib in combination with tegavivint as a potential first-line treatment for EGFR-positive NSCLC, which is exciting in a disease that is the No. 1 cause of cancer-related death in the United States."

"We are excited to collaborate with OSUCCC and the National Cancer Institute to initiate this Phase 1 first-line study of tegavivint in combination with osimertinib in previously untreated patients with metastatic EGFR-mutant NSCLC," said Rahul Aras, Ph.D., CEO of Iterion. "NSCLC is the most common type of lung cancer, accounting for 85% of all lung cancer diagnoses, according to the American Society of Clinical Oncology (ASCO). This trial has the potential to help this enormous patient population and to further demonstrate tegavivint's unique mechanism of action of TBL1 inhibition, thereby disrupting the oncogenic activity of beta-catenin. Tegavivint has already demonstrated safety in desmoid tumor patients and is currently being investigated in additional clinical trials as a potential treatment for acute myeloid leukemia and solid and hematologic pediatric tumors."

This Phase 1 clinical trial is funded by Pelotonia, a Columbus-based organization that has raised more than $236 million for cancer research conducted at the OSUCCC James, and the V Foundation.

About Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James)OSUCCC is one of 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both Phase 1 and Phase 2 clinical trials on novel anticancer drugs sponsored by the NCI. The James at Brain and Spine Hospital has been ranked one of the top cancer hospitals in the nation by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice.

About Iterion TherapeuticsIterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics. The company's lead product, tegavivint, is a potent and selective small molecule that binds to TBL1 in the nucleus inhibiting nuclear beta-catenin signaling and oncogenic activity. Research demonstrating potent anti-tumor activity in a broad range of pre-clinical models indicate that tegavivint has the potential for clinical utility in multiple cancer types. Currently, tegavivint is the subject of three separate clinical trials: a Phase 1 clinical trial sponsored by MD Anderson Cancer Center in patients with relapsed or refractory acute myeloid leukemia (AML); a Phase 1/2 clinical trial sponsored by Children's Oncology Group Pediatric Early Phase Clinical Trials Network in pediatric patients with sarcomas, lymphomas and other solid tumors, excluding central nervous system (CNS) tumors; and a Phase 1 clinical trial sponsored by Ohio State University Comprehensive Cancer Center in EGRF-positive non-small cell lung cancer (NSCLC). Data from a prior Phase 1/2a clinical trial of tegavivint in patients with progressive desmoid tumors demonstrated safety and preliminary clinical efficacy. Iterion is the recipient of an up to$15.9 millionProduct Development Award from the Cancer Prevention and Research Institute ofTexas (CPRIT).For more information on Iterion, please visit https://iteriontherapeutics.com.

ContactTiberend Strategic Advisors, Inc. Jason Rando (Media)917-930-6346[emailprotected]

1Shankar Suman, Shu-Xiao Guan, Nastaran Navari, Rajeswara Rao Arasada, David P. Carbone and Regan M. Memmott DOI: 10.1158/1538-7445.AM2021-1110Published July 2021. Proceedings from the AACR Annual Meeting 2021

SOURCE Iterion Therapeutics

View post:
Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Combination with Osimertinib in Epidermal Growth Factor...

DUBLIN, Oct. 15, 2021 /PRNewswire/ -- The "Global Agricultural Biotechnology Market 2020-2030 by Product, Technology, Application, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Global agricultural biotechnology market will reach $115.0 billion by 2030, growing by 9.8% annually over 2020-2030 owing to the rising population, the burgeoning demand for food, and the rising adoption of enhanced technologies for crop cultivation.

This report is based on a comprehensive research of the entire global agricultural biotechnology market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate and forecast from 2020 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global agricultural biotechnology market in every aspect of the classification from perspectives of Product, Technology, Application, and Region.

Key Topics Covered:

1 Introduction

2 Market Overview and Dynamics2.1 Market Size and Forecast2.1.1 Impact of COVID-19 on World Economy2.1.2 Impact of COVID-19 on the Market2.2 Major Growth Drivers2.3 Market Restraints and Challenges2.4 Emerging Opportunities and Market Trends2.5 Porter's Five Forces Analysis

3 Segmentation of Global Market by Product3.1 Market Overview by Product3.2 Biotech Seeds3.2.1 Biotech Seeds by Breeding Type3.2.2 Biotech Seeds by Trait Type3.2.3 Biotech Seeds by Crop Type3.3 Biologicals3.3.1 Biopesticides3.3.2 Biostimulants3.3.3 Biofertilizers3.3.4 Genetic Biologicals3.4 Biotechnology Tools3.4.1 DNA Sequencing3.4.2 Biochips3.4.3 Gene Editing3.4.4 Synthetic Biology3.4.5 RNA Interference3.5 Synthetic Biology-enabled Products3.5.1 Polymers3.5.2 Biofuels3.5.3 Enzymes3.5.4 Oils & Lubricants3.5.5 Other Renewables

4 Segmentation of Global Market by Technology4.1 Market Overview by Technology4.2 Genome Editing4.3 Synthetic Biology4.4 Genetic Engineering4.5 Marker-assisted Breeding4.6 Plant Breeding4.7 Germplasm4.8 Other Technologies

5 Segmentation of Global Market by Application5.1 Market Overview by Application5.2 Foliar Spray5.3 Seed Treatment5.4 Soil Treatment5.5 Other Applications

6 Segmentation of Global Market by Region6.1 Geographic Market Overview 2019-20306.2 North America Market 2019-2030 by Country6.2.1 Overview of North America Market6.2.2 U.S.6.2.3 Canada6.2.4 Mexico6.3 European Market 2019-2030 by Country6.3.1 Overview of European Market6.3.2 Germany6.3.3 U.K.6.3.4 France6.3.5 Spain6.3.6 Italy6.3.7 Russia6.3.8 Rest of European Market6.4 Asia-Pacific Market 2019-2030 by Country6.4.1 Overview of Asia-Pacific Market6.4.2 Japan6.4.3 China6.4.4 Australia6.4.5 India6.4.6 South Korea6.4.7 Rest of APAC Region6.5 South America Market 2019-2030 by Country6.5.1 Argentina6.5.2 Brazil6.5.3 Chile6.5.4 Rest of South America Market6.6 MEA Market 2019-2030 by Country6.6.1 UAE6.6.2 Saudi Arabia6.6.3 South Africa6.6.4 Other National Markets

7 Competitive Landscape7.1 Overview of Key Vendors7.2 New Product Launch, Partnership, Investment, and M&A7.3 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/hfydne

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Here is the original post:
Insights on the Agricultural Biotechnology Global Market to 2030 - Trend Forecasts and Growth Opportunities - PRNewswire

Dublin, Oct. 12, 2021 (GLOBE NEWSWIRE) -- The "Global Markets for Media, Sera and Reagents in Biotechnology" report has been added to ResearchAndMarkets.com's offering.

The current report offers a detailed picture of media, sera and reagents in biotechnology. This report highlights the current and future market potential for media, sera and reagents in biotechnology and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities and trends in the market.

This report also covers market projections through 2026 and key market players.

The global market for media, sera and reagents in biotechnology is estimated to grow from $5.0 billion in 2021 to $7.4 billion by 2026 at a compound annual growth rate (CAGR) of 7.9% of during the forecast period of 2021-2026.

North American market for media, sera and reagents in biotechnology is estimated to grow from $1.7 billion in 2021 to $2.3 billion by 2026 at a CAGR of 5.9% of during the forecast period of 2021-2026.

Asia-Pacific market for media, sera and reagents in biotechnology is estimated to grow from $1.2 billion in 2021 to $1.9 billion by 2026 at a CAGR of 9.5% of during the forecast period of 2021-2026.

The report details market shares of media, sera and reagents in cell culture. Market analysis in the media segment is divided into specialty media and classical media based on composition.

Based on formulation, the media are divided into powdered media and ready-to-use liquid media. Based on serum component, media are segmented into serum-free media and serum-requiring media. The market for sera is segmented based on the source of serum into fetal bovine serum and other sera which includes sera from animal sources such as goats, porcine, rabbits, etc.

The reagents market is segmented into reagents: biological response modifiers, cell dissociation reagents and others (amino acids, antibiotics, etc.). By geography, the market has been segmented into North America, Europe, the Asia-Pacific region, Middle East and Africa and South America. North America includes the U.S., Canada and Mexico, Europe includes Germany, the U.K., France, Italy, Spain and the Rest of Europe. The Asia-Pacific region includes China, India, Japan, Australia, New Zealand and the Rest of Asia-Pacific.

Story continues

Report Includes:

61 data tables and 44 additional tables

An updated review of current and future global markets for media, sera and reagents in the cell culture industry and its sub-segments

Analyses of the global market trends, with data from 2019-2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026

Discussion of major factors driving the growth of this market, industry structure, regulatory scenario, and penetration of technologies related to media, sera, and reagents in biotechnology

Estimation of the market size and market forecast for global media, sera, and reagents in biotechnology, and corresponding market share analysis by product type, end use, and region

Country specific data and market value analysis for the U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, Japan, China, India, Australia and New Zealand, the Middle East and Africa

Highlights of emerging technology trends, opportunities and gaps estimating current and future demand for cell culture products; and impact analysis of COVID-19 on the progress of this market

A relevant patent analysis with significant allotments of patent issued for cell culture media, sera and reagents in biotechnology across each major category

Insight into the recent industry strategies, M&A deals of the major players operating within the global market; their key competitive landscape and company share analysis

Profile descriptions of the leading industry players, including Bio-Techne, Corning Inc., Fujifilm Holdings Corp., GE Healthcare, Merck KGaA and Thermo Fisher Scientific Inc.

Cell culture is the in vitro cultivation of cells in a controlled environment. Cell culture is gaining importance in biopharmaceutical industries with the growing demand for cell culture techniques in drug discovery and the production of biotherapeutics. Cell culture is used in academic research institutes to understand the physiology and biochemistry of cells.

Media, sera and reagents play an important role in the success of cell culture technology. The growing demand for novel therapeutics for the treatment of chronic disease and extensive research activities in regenerative medicine are anticipated to create high growth for media, sera and reagents during the forecast period.

The intent of this study is to provide readers with detailed information regarding cell culture, along with factors influencing market and key developments, with the goal of enabling decision-making regarding expansion and penetration in this market.

This report seeks to address the critically important topics of changing market dynamics, emerging players and technologies, strategies for accessing emerging markets and specific disease segments and geographies.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Industry Definitions

Historical Background of the Evolution of Cell Culture

Types of Cell Culture

Primary Culture

Secondary Culture

Morphology of Cells in Culture

Cell Culture Contamination and Quality Control

Cell Culture Contamination

Quality Controls in Cell Culture

Basic Components of Culture Media

Buffering Systems

Phenol Red

Inorganic Salts

Amino Acids

Carbohydrates

Proteins and Peptides

Fatty Acids and Lipids

Vitamins

Trace Elements

Media Supplements

Antibiotics

Serum

Cell Culture Applications

Chapter 4 Impact of COVID-19 Pandemic

Chapter 5 Market Dynamics

Market Drivers

Growing Demand

Technological Advancements

Expansion of Cell Cultures

R&D and Regenerative Medicines

Market Restraints

Ethical Issues and Regulatory Constraints

Lack of Skilled Technicians and Poor Infrastructure

Market Opportunities

Rising Demand for 3D Cell Cultures

Drug Discovery and Growing CRO

Chapter 6 Market Breakdown by Product Type

Global Market for Media, Sera and Reagents in Biotechnology, by Product Type

Reagents

Biological Response Modifiers (BRMs)

Cell Dissociation Reagents

Other Reagents

Market Size and Forecast

Media

Based on Serum

Based on Formulation

Based on Composition

Market Size and Forecast

Sera

Bovine Sera/Fetal Bovine Sera

Other Sera

Market Size and Forecast

Chapter 7 Market Breakdown by End Use

Chapter 8 Market Breakdown by Region

Chapter 9 Regulatory Scenarios

Introduction

Biological License Applications

Biological Administrative Actions

Recalls

Serum Regulatory Scenario

Chapter 10 Competitive Landscape

Chapter 11 Patent Analysis

Patents Granted by Year

Patents Granted by Type

Patents Granted by Company/Patent Holder

Patents Granted by Assignee's Country

Patents Granted by Assignee Type

Chapter 12 Company Profiles

Athena Environmental Sciences Inc.

Bio-Techne

Becton, Dickinson And Co. (Bd)

Go here to read the rest:
The Worldwide Media, Sera and Reagents in Biotechnology Industry is Expected to Reach $7.4 Billion by 2026 - Yahoo Finance

SAN CARLOS, Calif., October 11, 2021--(BUSINESS WIRE)--AcureX Therapeutics Corporation, a privately-held preclinical-stage biotechnology company focused on developing disease altering therapeutics for neurodegenerative diseases, today announced that it was selected to present at the Oppenheimer Biotechnology Emerging Science Summit on October 15th, 2021.

Presentation details:

Halting Neurodegeneration with Miro1 Directed TherapiesPresented by: William Shrader, Ph.D., Co-founder and CEO AcureX TherapeuticsDate and time: October 15th, 2021 at 1:30p.m. ET / 10:30a.m. PT

The Oppenheimer Biotechnology Emerging Science Summit will be held virtually and will feature Stanford Universitys SPARK program. Presentations will be given by experts in the fields of oncology, immunology, neurology, and gene therapy, as well as management from several publicly traded companies.

William Shrader, Ph.D. said, "We at AcureX are pleased to be recognized as a leader in an emerging field and we are delighted to share our novel drug discovery approach at this prestigious forum."

About AcureX Therapeutics

The mission of AcureX Therapeutics is to halt neurodegenerative diseases driven by impaired mitophagy, starting with Parkinsons Disease. AcureX expects to have one or more late-preclinical therapeutic candidates for Parkinsons in human trials within two years, followed by candidates for other neurodegenerative diseases. AcureXs novel approach and founding intellectual property are based on recent discoveries made by the companys inventor and co-founder, Xinnan Wang MD, Ph.D. AcureX has built a unique target and drug discovery platform to accelerate drug development and de-risk clinical trials with an exclusive license to the founding intellectual property. The AcureX team is led by veteran scientists with a proven track record in CNS drug development and serial life sciences entrepreneurs. For more information, please visit https://www.acurex.com.

Story continues

Oppenheimer Biotechnology Emerging Science Summit Registration

To express interest, please contact your Oppenheimer Institutional Salesperson or email Deena Sullivan at Deena.Sullivan@opco.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005102/en/

Contacts

Ashley Gonzalez, Ph.D.Info@acurex.com

Originally posted here:
AcureX Therapeutics to Present at Oppenheimer Biotechnology Emerging Science Summit - Yahoo Finance

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

NEW YORK, NY / ACCESSWIRE / October 15, 2021 / Sino United Worldwide Consolidated Ltd. (OTC PINK:SUIC) and Midas Touch Technology Ltd. have signed a strategic alliance partnership agreement with Taiwan Green Mountain Biotechnology Group to lead the countrywide marketing promotional activities and roadshows to kick off this quarter, aiming to establish 6,000 outlets in Taiwan and 30 other countries. SUIC, Midas are finalizing contracts with additional 5 partner distributors before the end of this year.

The partnership agreement was completed by the founder and Chairman of Green Mountain Biotechnology Group, Mr. Lin Jye and the CEO of Midas Touch, Mr. Joa Chen during a well-appointed signing ceremony hosted at the Taipei Regent Hotel on October 8, 2021 and attended by hundreds of merchants. The signing event had been widely covered by major media.

The Green Mountain Biotechnology Group is a leading beauty company in Taiwan specializing in manufacturing and marketing top quality skin care, makeup, fragrance and hair care products. The group Chairman, Mr. Lin Jye said, "This partnership with Midas Touch brings a positive energy that will benefit hundred thousands of business partners and generate tens of billions of dollars in business opportunities, while creating more than a million jobs in all parts of the world. Midas Touch has the mastery of operations and inventive approach that is unique and unparalleled in the market."

The Green Mountain Biotechnology group of companies has ten major business segments with a global scope covering more than 30 countries around the world. The holding group has captured the focus of major international media. It is one of the very few biotech companies in Taiwan that possesses cutting-edge technology research and development capabilities, global advanced production technology, and integrated brand marketing. The current product range covers medical and aesthetic skin care products, daily chemicals, nutritional supplements and smart living drinking water systems. Among the accolades it has gathered over the decades, its biotechnology company has received high recognition and won awards including the Taiwan Biotechnology Award, the Taiwan's No. 1 Brand Award, and the Taiwan Golden Quality Award, and the Global Quality Certification of Taiwan Ministry of Health. In addition to the Chinese market, the group's products are exported to more than 30 countries including the United States, Japan, South Korea, Malaysia, Singapore, the European Union, Thailand, Indonesia, Hong Kong, Macau, among others.

To learn more about Green Mountain Biotechnology group, please visit their website at:https://meihangjia.com/contact-us/

"SUIC-Midas is the first U.S. company that brings unique blockchain based solutions to Taiwan market for the digitization of real-world assets, unlocking their value in the process. We are very honored to have this opportunity to join the ranks of this pioneering "Supply Chain of Beauty" project and provide flexible funding strategies to businesses in the beauty industry and other industries in Taiwan and around the world. SUIC Midas not only offers one-of-a-kind solutions but also opportunities to grow businesses on a secure digital platform without losing the original characteristics of the physical assets. In January 2022, SUIC Midas will continue signing up more partners, while exclusive interviews with NASDAQ, Bloomberg, Fox Business and other major business news televisions have also been scheduled. This is a part of our global expansion plans to disrupt the traditional cash flow system and lead to the next generation of SUIC Midas supply chain finance ecosystem," explains Midas Touch media director, Henry Ho.

These five new partner distributors are expected to bring over 100,000 merchants which translates to $2 million royalty fees for the Midas Touch office in Taiwan. The New York and Malaysia offices will follow suit and launch the Starry Project before the end of the year, and will continue to launch in 40 countries in 2022/2023 replicating the Starry Project model and strategy.

About Midas Touch Technology Limited, United KingdomMidas Touch Technology Limited was established in the United Kingdom in 2010, is a duly registered company with a business license to operate. Midas Touch offers safeguards against fraud in the digital currency domain, e.g. counterfeit transfer of digital cash in wallets. Focus on digital asset management and provides enterprises with a decentralized finance (DeFi) and other comprehensive supply chain innovative financial services. Thereby, solve the capital turnover problems in both supply and demand sites. It has launched MT Flash Pay" Same Day Swipe-Funding, and MT CQ Pay" Emergency Loan with Double Revenues, MT Free Pay" Services - Delay Appropriation to Offset Transaction Cost and MT Unified Procurement" Combined Purchasing Powers Economies of Scale and several other financial solutions. To know more about Midas Touch, visit their website at http://www.midas-touch.io.

To learn more about Midas Touch product and services please review our information by clicking:https://drive.google.com/file/d/17GLXWv5T3d39Jrx2v0GvqKIBcSzxpOMy/view?usp=drivesdk

About Sino United Worldwide Consolidated Ltd., USAThe Sino United Worldwide Consolidated Ltd. provides research and development, venture financing for and investing in private enterprises and the public sector that develop products and services adopting core capabilities of the Internet of Things, cloud computing, mobile payment, Big Data, Blockchain, and Artificial Intelligence, to enhance and streamline existing processes, and establish new and exciting business models that will create revolutionary products and services. Shareholders of SUIC will be exposed to the diverse application of advanced services in various parts of the economy. Additionally, existing and potential customers can benefit from this company's diversified portfolio of technologies. As one of the pioneering publicly traded technology companies, SUIC will help build tech-enabled businesses of the future. To learn more, please visit http://www.sinounitedco.com.

Please also read the full company report on SUIC by Globe Small Cap Research LLC:https://drive.google.com/file/d/1_f2vaVOfJT5_idLn87lM1Q_lGxnY_tHW/view

Please also read the Updated Company PPT:https://drive.google.com/file/d/1jVOkxqxXFCRwrajwTQQ7xV7YIzn5wWF_/view?usp=sharing

Forward-Looking StatementCertain the information set forth herein contains "forward-looking information", including "future-oriented financial information"; and "financial outlook" under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of shares being offered hereunder; (iii) the expected development of the Company's business, projects, and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development, or otherwise under consideration; (vi) renewal of the Company's current agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained herein are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

ContactsSino United Worldwide Consolidated Ltd.New Release Department929-391-2550

SOURCE: Sino United Worldwide Consolidated Ltd.

View source version on accesswire.com: https://www.accesswire.com/668099/SUIC-Midas-Signed-Strategic-Partnership-Agreement-With-Taiwan-Biotech-Giant--Green-Mountain-Biotechnology-Group-To-Lead-The-Starry-Project-Countrywide-Roadshow-and-Global-Expansion-To-Open-6000-Outlets-in-30-Countries-SUIC-Midas-Is-Finalizing-The

The rest is here:
SUIC, Midas Signed Strategic Partnership Agreement With Taiwan Biotech Giant - Green Mountain Biotechnology Group To Lead The Starry Project...

Renowned industrialist and founder chairman of Praj Industries, Dr Pramod Chaudhari, who is popularly known as the Ethanol man, recently said that agricultural inputs form the base of biotechnology and these can be used to uplift the socio-economic status of farmers. Dr Chaudhari was speaking at an event held in his honour and hosted by United Western Business Forum at Hotel Sayaji in Wakad.

Dr Chaudhari was felicitated by Dr Anand Deshpande, the CMD of Persistent Systems, for being the first Indian recipient of the prestigious George Washington Carver Award, 2020.

Pune Mayor Murlidhar Mohol and PMRDA (Pune Metropolitan Region Development Authority) Commissioner Dr Suhas Diwase also attended the programme.

Dr Chaudhari said that biofuels are redefining transportation fuel mix and they also help combat climate change as they have low carbon content. The use of agricultural feedstock for production of biofuels provided an additional source of income to farmers, he added. Dr Chaudhari said that bio-based renewable chemicals and materials are the new frontier of bioeconomy.

Mohol said Dr Chaudharis achievement is a matter of pride for Puneites and added that People like Dr Chaudhari will inspire the youth of the city.

Dr Deshpande said an entrepreneur should always think about achieving the next level for his business, because any business can stagnate after reaching a certain level of success. He also suggested that a wide base of mentors was required to guide the entrepreneurs through difficult times.

The dean of alumni and corporate relations at IIT Bombay, Dr Suhas Joshi, said that the institute was in advanced stages of discussions with Dr Chaudhari for setting up a lifelong learning centre for IIT-B alumni. The institute has a strong base of over 65,000 alumni working across various segments and they have an urge to learn new skills from their alma mater, Joshi added.

Dr Diwase pointed out that biotechnology had the potential to make agriculture sustainable and economically viable. This will also help reduce urban influx and ease pressure on cities, he said. The current Covid-19 pandemic has shown the youth the importance of moving back to the fields rather than seeking opportunities in big cities, he said.

Read more from the original source:
Biotechnology can be used to improve condition of farmers, says Ethanol man - The Indian Express